Catalyst Dossier · compiled by CeliA 🧫

ALK-Abelló A/S (ALK-B.CO)

Pharmaceutical Preparations · market cap $8.1B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-06 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

ALK-Abelló A/S (ALK-B.CO) is a Danish specialty pharma company with 2,759 employees and a market cap of approximately $8.07B, focused exclusively on allergy immunotherapy (AIT) across subcutaneous, sublingual tablet, and sublingual drop modalities. The company fields a broad pipeline spanning house dust mite (HDM), grass pollen, tree pollen, and cat allergen programs across rhinitis, allergic rhinoconjunctivitis, asthma, and atopic dermatitis indications. The nearest binary event is a Phase 3 readout for the HDM SLIT-tablet (12 SQ-HDM) expected around September 6, 2026.

The catalyst path

2026-09-06 (est.)Phase 3 · HDM SLIT-tablet (12 SQ-HDM)imp 9/10

Pipeline

Asset	Phase	Indication
ALK HDM tablet	Phase 3	Asthma
MK-8237 6 DU	Phase 2	Rhinitis, Allergic, Perennial
AVANZ Salsola	Phase 2	Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen
ALK Grass tablet - use of compliance device	Phase 3	Allergy
AVANZ Phleum pratense 15,000 SQ+	Phase 2	Grass Pollen Induced Allergic Rhinoconjunctivitis
Sublingual allergy immunotherapy tablet	Phase 3	Allergic Rhinitis Due to Dermatophagoides Farinae
AVANZ Phleum pratense	Phase 3	Allergic Rhinoconjunctivitis
Grass (Phleum pratense) pollen allergen extract	Phase 3	Rhinitis Allergic
AIT Tablet	Phase 3	House Dust Mite Allergy
Specific allergen immunotherapy	Phase 2	Cat Allergy
Ambrosia artemisiifolia allergen extract (Amb a 1-U)	Phase 3	Rhinitis, Allergic
ALK Grass tablet	Phase 3	Allergy
Grazax + Aerius	Phase 3	Allergic Rhinoconjunctivitis
Loratadine 10 mg Rescue Treatment	Phase 3	Rhinoconjunctivitis
SCH 39641	Phase 3	Allergy
Allergy vaccination (Alutard SQ)	Phase 3	Allergy
subcutaneous immunotherapy	Phase 3	Atopic Dermatitis
Pangramin SLIT HDM mix.	Phase 3	Allergic Rhinitis
HDM SLIT-tablet	Phase 3	Allergic Rhinitis
Tree SLIT-tablet	Phase 3	Allergy

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALK-B.CO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.